CROI 2013 Eric Lawitz, Alamo Medical Research, presenting at CROI 2013. © Liz Highleyman / hivandhepatitis.comAbbVie combinationResults study into interferon-free combination. Isabelle Poizot-Martin and Laurent Cotte at CROI 2013. © Liz Highleyman / hivandhepatitis.comReal-world dataTelaprevir and boceprevir in HIV/hepatitis C co-infection. Anu Osinusi, National Institute of Allergy and Infectious Diseases, presenting at CROI 2013. © Liz Highleyman / hivandhepatitis.comSofosbuvir plus ribavirinGood results for hard-to-treat inner-city group. infohep news Interferon-free regimens AbbVie interferon-free combinations cure most newly treated hepatitis C patients Liz Highleyman / 20 March 2013 All-oral regimens consisting of the HCV protease inhibitor ABT-450, a non-nucleoside polymerase inhibitor and ribavirin led to sustained response for more than 90% of previously untreated hepatitis C patients – including those ... Interferon-free regimens Sofosbuvir plus ribavirin works well for hard-to-treat inner-city hepatitis C patients Liz Highleyman / 20 March 2013 A simple 24-week oral regimen consisting of sofosbuvir plus full-dose ribavirin cured nearly 70% of previously untreated people with genotype 1 hepatitis C, many of whom had factors predictive of poor response, researchers reported ... Interferon-free regimens Simeprevir & sofosbuvir demonstrates good early cure rate with or without ribavirin Liz Highleyman / 12 March 2013 An all-oral combination of simeprevir plus sofosbuvir, with or without ribavirin, led to an early cure for most hard-to-treat prior null responders with genotype 1 hepatitis C studied in the phase 2a COSMOS ... Treatment in acute infection Adding telaprevir improves acute hepatitis C treatment for HIV-positive men Liz Highleyman / 12 March 2013 Adding telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin shortens the duration of treatment and increases the likelihood of a cure for HIV-positive men with acute sexually transmitted hepatitis C virus ... Treatment for people living with HIV and HCV Simeprevir pushes HCV cure rate above 75% for HIV/HCV co-infection Liz Highleyman / 11 March 2013 Adding the new hepatitis C virus (HCV) protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cures about three-quarters of HIV/HCV co-infected people, most of them with a shortened course of therapy, ... Treatment for people living with HIV and HCV Faldaprevir ups interferon response in HIV/HCV co-infection Liz Highleyman / 11 March 2013 Adding the hepatitis C virus (HCV) protease inhibitor faldaprevir (formerly BI 201335) to pegylated interferon and ribavirin led to a higher early response rate and the potential for shorter treatment for HIV/HCV co-infected ... Treatment for people living with HIV and HCV French studies report real-world data on use of telaprevir and boceprevir in people with HIV and hepatitis C co-infection Liz Highleyman / 05 March 2013 Adding boceprevir or telaprevir to interferon-based therapy showed promising indications of efficacy and acceptable safety for difficult-to-treat HIV/HCV co-infected prior non-responders in a pair of French studies presented yesterday at the 20th Conference on Retroviruses and ... Interferon-free regimens Sofosbuvir/ledipasvir/ribavirin cures 100% of genotype 1 hepatitis C patients Liz Highleyman / 05 March 2013 An interferon-free regimen containing sofosbuvir (formerly GS-7997), ledipasvir (formerly GS-5885) and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive hepatitis C patients and prior interferon non-responders, according ... View more > Editors' picks from other sources Treatment for previous non-responders & relapsers Telaprevir shows promise in black patients with genotype 1 HCV Healio / 12 March 2013 View more > Other pages in this section Latest news All the news Conference news Email bulletin archive